Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660342 · ClinicalTrials.gov registry record
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
A clinical trial of Heartburn and Erosive Esophagitis, sponsored by Phathom Pharmaceuticals.
- Recruiting
- Registry status
- 728
- Enrollment target
- 1
- Study location
NCT06660342: Recruiting study of Heartburn and Erosive Esophagitis, sponsored by Phathom Pharmaceuticals.
NCT06660342 is a study of Heartburn and Erosive Esophagitis that is actively recruiting participants, run by Phathom Pharmaceuticals. The registered enrollment target is 728 participants, above the 339-participant average among 9 other Heartburn trials with a reported enrollment target (115% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06660342, a study of Heartburn and Erosive Esophagitis, is actively recruiting participants, sponsored by Phathom Pharmaceuticals.
- RECRUITING
- Registry status
- 728 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are unexposed to vonoprazan during pregnancy but who may be exposed to other products for the treatment of conditions for which vonoprazan may be prescribed.
Conditions Studied
Interventions
- DRUG Vonoprazan
Study Locations (1)
North Carolina
- PPD - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2034-09 |
What NCT06660342 shows while recruiting
NCT06660342 is an observational study that tracks outcomes without assigning an intervention. The registered 728 participants enrollment target is mid-sized for trials with a published cap, above the 339-participant average among 9 other Heartburn trials with a reported enrollment target (115% higher).
The record links to 4 conditions, with Heartburn appearing as the primary indexed condition, and to 1 intervention - of which Vonoprazan is the first listed.
NCT06660342 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06660342 about?
NCT06660342 is a clinical study titled "A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring". The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are unexposed to vonoprazan during pregnancy but who may be exposed to other pr...
What is the current status of trial NCT06660342?
This trial is currently recruiting. The enrollment target is 728 participants. The study started on 2025-05-15. Estimated completion is 2034-09.
What conditions does trial NCT06660342 study?
This clinical trial studies the following conditions: Heartburn, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Non-erosive Gastroesophageal Reflux Disease.
What interventions are being tested in trial NCT06660342?
The interventions under investigation include: Vonoprazan (DRUG).
Who is sponsoring clinical trial NCT06660342?
This trial is sponsored by Phathom Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660342 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heartburn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06660342's enrollment target sits among peer trials
728 1st of 9 higher than 9 of 9 other Heartburn trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heartburn trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
COMPLETED · Phase 3
-
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
COMPLETED · Phase 3
-
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
COMPLETED · Phase 3
-
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
- NCT06433765 · 728 participants
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI